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yeloperoxidase Predicts
rogression of Carotid Stenosis in States
f Low High-Density Lipoprotein Cholesterol
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asmin Amighi, MD,† Wolfgang Lalouschek, MD,‡ Gerald Maurer, MD,§ Christian Bieglmayer, PHD,*
eidi Kieweg,* Oswald Wagner, MD,* Martin Schillinger, MD†
ienna, Austria
OBJECTIVES We investigated the effect of myeloperoxidase (MPO) on progression of carotid stenosis in
states of high and low high-density lipoprotein-cholesterol (HDL-C) and low-density
lipoprotein-cholesterol (LDL-C) levels.
BACKGROUND Myeloperoxidase is pivotally involved in the pathogenesis of atherosclerosis. In vitro data
suggest that MPO exerts deleterious effects via oxidative modulation of lipoproteins.
METHODS We prospectively studied 1,019 of 1,268 consecutive patients who were asymptomatic with
respect to carotid artery disease. Patients underwent serial carotid ultrasound investigations at
baseline and after a follow-up interval of median 7.5 months (range 6 to 9 months),
categorizing carotid arteries as 0% to 29%, 30% to 49%, 50% to 69%, 70% to 89%, or 90%
to 99% stenosed or occluded. The MPO, HDL-C, and LDL-C levels were measured at
baseline, grouped by medians, and correlated with progression of carotid atherosclerosis.
RESULTS Progression of carotid atherosclerosis was found in 100 of 1,019 patients (9.8%). Myeloper-
oxidase (p  0.014) but not HDL-C (p  0.95) or LDL-C (p  0.30) were associated with
progressive disease. However, MPO310 ng/ml was significantly associated with progressive
disease (adjusted odds ratio [OR] 2.57, 95% confidence interval [CI] 1.39 to 4.75) only in
patients with HDL-C levels 49 mg/dl. Otherwise, in patients with higher HDL-C levels
(49 mg/dl), MPO310 ng/ml did not predict disease progression (adjusted OR 1.42, 95%
CI 0.72 to 2.78). No interaction of MPO with LDL-C was observed.
CONCLUSIONS Myeloperoxidase was associated with progression of carotid atherosclerosis in patients with
HDL cholesterol levels below 49 mg/dl. (J Am Coll Cardiol 2006;47:2212–8) © 2006 by
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.01.067the American College of Cardiology Foundation
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secent evidence suggests that myeloperoxidase (MPO), a
emoprotein with mainly microbicidal properties, is funda-
entally involved in the development of atherosclerotic
esions (1). Myeloperoxidase seems to play a potentially
mportant role in promoting the progression of pre-existent
therosclerosis, thus triggering the occurrence of acute
ascular events. Leukocyte- and blood-MPO levels are
ignificantly higher in patients with coronary artery disease
ompared with healthy control subjects (2), and elevated
PO levels in patients with acute chest pain and acute
oronary syndromes identify individuals with increased risk
or an adverse cardiovascular outcome (2–4).
Imbalance between oxidative proatherogenic factors and
ntiatherogenic mechanisms is a key feature in the patho-
enesis of atherosclerosis (5,6). Myeloperoxidase has been
etected in human atherosclerotic lesions (7) and is essen-
ially involved in the catalytic consumption of nitric oxide,
mpairing endothelium-dependent vasorelaxation (8–10).
yeloperoxidase directly activates metalloproteinases and
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Angiology, ‡Neurology, and §Cardiology, Medical University Vienna, Vienna,
ustria.c
Manuscript received November 7, 2005; revised manuscript received January 11,
006, accepted January 16, 2006.acilitates destabilization and rupture of the vulnerable
laque (11,12). However, a major part of MPO’s deleterious
ffects on the vasculature seems to be mediated via oxidative
odification of lipoproteins. In vitro studies demonstrated
hat MPO catalyzes oxidative modification of high-density
ipoprotein (HDL) (13) leading to the development of
ysfunctional proinflammatory and proatherogenic HDL
14,15), a finding which recently has been confirmed in vivo
n human atherosclerotic tissue (16). Myeloperoxidase also
atalyzes low-density lipoprotein (LDL) modification, thus
acilitating its uptake by macrophages (17–22). Macro-
hages thereby convert into foam cells, which are charac-
eristic of early atherosclerotic lesion formation.
We hypothesized that an interaction of MPO with
ipoproteins (HDL and LDL) in the circulation may be
ssociated with progression of atherosclerotic disease as-
uming that MPO may differentially exert its deleterious
ffects depending on patients’ HDL and LDL levels.
herefore, the aim of the present study was to investigate the
ssociation between progression of the degree of carotid ste-
osis measured by high-resolution duplex ultrasound and
ystemic MPO serum levels in states of low and high HDL-
holesterol (HDL-C) and LDL-cholesterol (LDL-C) levels.
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tudy design. We prospectively enrolled 1,268 consecutive
aucasian patients in the Inflammation in the Carotid
rteries Risk for Atherosclerosis Study (ICARAS) proto-
ol. Analysis of MPO as a candidate predictive biomarker
as prespecified in the original ICARAS protocol. Study
esign, patient characteristics, and the association between
-reactive protein (CRP) and serum amyloid A (SAA) with
rogression of carotid atherosclerosis have been reported
23). Briefly, patients without recent symptoms of carotid
rtery disease, defined as the absence of transient ischemic
ttacks, amaurosis fugax, or stroke 12 months before inclu-
ion, assessed by a neurologist, underwent serial carotid
uplex ultrasound investigations at baseline and after a six-
o nine-month interval (median 7.5 months). Primary study
nd point was uni- or bilateral progression of carotid
therosclerosis in the extracranial internal carotid arteries
ICA), measured by duplex ultrasound. In the current study,
e aimed to directly evaluate progression of atherosclerotic
tenosis instead of measuring surrogate markers of carotid
isease (such as intima-media thickness); therefore, changes
n the degree of stenosis were used as a measure of plaque
rogression.
For the current analysis, we included 1,019 of 1,268
atients (80%) in whom MPO and HDL cholesterol levels
ould be obtained at the baseline visit. The study complied
ith the Declaration of Helsinki and was approved by
nstitutional ethics committee. All patients provided written
nformed consent.
arotid ultrasound. We used the following categories to
uantify the degree of ICA stenosis at baseline and follow-
p: 0% to 29% (carotid plaques), 30% to 49% (advanced
laques), 50% to 69% (moderate stenosis), 70% to 89%
Table 1. Grading of Carotid Artery Stenosis b
Angiographic Degree of Stenosis
0%–29% 30%–49%
PSVICA/PSVCCA 1.4 1.5–1.9
PSVICA 120 120–149
Flow velocities are given in mm/s.
Abbreviations and Acronyms
CI  confidence interval
CRP  C-reactive protein
HDL-C  high-density lipoprotein cholesterol
hs-CRP  high-sensitivity C-reactive protein
ICA  internal carotid artery
IQR  interquartile range
LDL-C  low-density lipoprotein cholesterol
MPO  myeloperoxidase
OR  odds ratio
SAA  serum amyloid ACCA  common carotid artery; ICA  internal carotid art
Endarterectomy Trial; PSV  peak systolic velocity.high-grade stenosis), 90 to 99% (subocclusive stenosis), and
cclusion (Table 1). Progression of carotid disease was
efined as an increase of the degree of stenosis by at least
ne category. Progression of stenosis in either one or both
CAs was considered to be indicative of progressive disease.
secondary objective was the change of the peak systolic
elocity in the ICA (PSVICA) from baseline to follow-up,
eflecting a continuous surrogate marker for the extent of
rogressive carotid disease.
The agreement of duplex ultrasound with respect to
orth American Symptomatic Carotid Endarterectomy
rial angiographic criteria was assessed previously in our
uplex laboratory in an independent cohort including 1,006
arotid arteries (24) Positive and negative predictive values
anged from 70% to 98%, and interobserver agreement with
espect to the degree of stenosis was excellent (kappa 0.83,
5% confidence interval [CI] 0.79 to 0.88). Experienced
edical technicians under supervision by one of the authors
id all duplex recordings, and baseline and follow-up
nvestigators for the same patient varied randomly and were
linded for the baseline ultrasound findings. Two indepen-
ent investigators (kappa 0.85, 95% CI 0.80 to 0.89)
etermined progression of carotid atherosclerosis based on
he recordings from baseline and follow-up duplex investi-
ations. We censored duplex follow-up for ischemic neuro-
ogic events and carotid revascularization.
linical and laboratory data. After patient identification
t the ultrasound laboratory, medical history and data from
hysical examination were recorded. We screened for infec-
ious or inflammatory diseases by evaluating patients’ clin-
cal history and current symptoms. Clinical suspicion for
nfectious or inflammatory diseases prompted further spe-
ific investigations according to clinical judgment. Criteria
or definitions of risk factors and comorbidities correspond
o current recommendations and are listed in the ICARAS
rotocol (23).
Antecubital venous blood samples were obtained at base-
ine visits. Measurements included HDL, LDL, and total
holesterol, glycated hemoglobin A1, high-sensitivity CRP
hs-CRP), SAA, fibrinogen, and complete blood count.
erum MPO at baseline was measured by enzyme-linked
mmunosorbent assay (Immundiagnostik, Bensheim, Ger-
any) according to the manufacturer’s instructions (detec-
ion level 1.6 ng/ml, coefficient of variation 6.5%). Treating
hysicians and ultrasonographers were blinded for all labo-
atory values.
plex Ultrasound in Correlation With the
ASCET Grade
69% 70%–89% 90%–99% 100%
3.9 4.0 — —
249 250 Trickle flow No flowy Du
N
50%–
2.0–
150–ery; NASCET  North American Symptomatic Carotid
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Myeloperoxidase and HDL June 6, 2006:2212–8edication. Pharmacotherapy of patients with evidence of
therosclerosis followed a standard protocol: Patients re-
eived antithrombotic therapy with either 100 mg acetylic
alicylic acid or 75 mg clopidogrel once daily. Patients with
yperlipidemia (LDL-C 130 mg/dl) received inhibitors
f the 3-hydroxy-3-methylglutaryl coenzyme A reductase
statins); statin therapy was intended not to be de novo or
hanged during the study period.
tatistical methods. Continuous data are presented as
edian and interquartile range (IQR, range from the 25th
o the 75th percentile) or total range. Discrete data are given
s counts and percentages. We used chi-square tests, Mann-
hitney U tests, and Spearman correlation coefficients for
nivariate analyses as appropriate. Assessment of an inter-
ction between MPO and lipoproteins (HDL and LDL) as
study objective was prespecified before starting the labo-
atory and biometric analysis on MPO. Multivariable logis-
ic regression analysis was applied to assess the joint effects
f MPO and HDL-C or LDL-C on progression of the
isease, adjusting for potential confounders. The MPO and
DL-C or LDL-C levels were divided into quartiles before
eing entered jointly into the models to obtain clinically
seful measures for the effect sizes. Interaction between the
arameters was assessed by multiplicative interaction terms
nd log likelihood ratio tests. To account for an interaction
etween MPO and HDL-C or LDL-C, we grouped
atients in a predefined approach according to low and high
PO and lipoprotein levels using the respective medians as
ut-off values, resulting in four similarly sized groups.
esults of the logistic regression models are presented as the
dds ratio (OR) and the 95% CI. The linearity of the logic
ssumption was checked for continuous predictor variables,
nd an analysis of residuals was performed. Regression
iagnostics and overall model fit were performed according
o standard procedures (25). A two-sided p value of 0.05
as considered to be statistically significant. Calculations
ere performed with Stata release 8.0 (Stata Corp., College
tation, Texas) and SPSS for Windows version 10.0 (SPSS
nc., Chicago, Illinois).
ESULTS
atients. We analyzed 1,019 of 1,268 patients (80%) of the
CARAS trial cohort with complete baseline and follow-up
ata and available serum samples for determination of MPO
evels. Median age of these patients was 69 years and 62%
ere males. Demographic data and clinical characteristics
re given in Table 2. These variables were statistically not
ignificantly different to the complete study population of
,268 patients enrolled in the ICARAS protocol.
In 249 patients (20%) serum samples for MPO measure-
ent were not available. Baseline characteristics and pro-
ortion of patients with progressive disease within these 249
atients were comparable with the entire study population
f 1,268 patients (data not shown). AThe MPO levels at baseline were median 310 ng/ml
IQR 220 to 416 ng/ml), and HDL-C and LDL-C levels at
aseline were median 49 mg/dl (IQR 41 to 61 ng/ml) and
18 mg/dl (IQR 93 to 147 ng/ml), respectively. Myeloper-
xidase and HDL-C were weakly negatively correlated (r 
0.083; p  0.013). Myeloperoxidase showed no correla-
ion with LDL-C (r  0.02; p  0.52). Patients with a
istory of stroke tended to have higher MPO levels (median
68 ng/ml, IQR 348 to 585 vs. median 425 ng/ml, IQR 300
o 583; p  0.055). There were no significant associations
etween MPO levels and symptoms of coronary artery
isease (p  0.55), history of myocardial infarction (p 
.49), or symptoms of peripheral artery disease (p  0.96).
ollow-up. During the follow-up period of median 7.5
onths (range 6 to 9 months), 100 of 1,019 patients (9.8%)
howed an increase in the degree of carotid stenosis by at
east one category. Of these, 42 patients (4.1%) showed
rogression of a left ICA stenosis, 52 patients (4.1%) of a
ight ICA stenosis, and 6 patients (0.6%) in both ICAs.
able 2. Demographic Data and Clinical Characteristics of the
tudy Patients (n  1,019)
n (%) or Median (IQR)
ge, yrs 69 (61–76)
ale/female 627 (62%)/392 (38%)
ody mass index, kg/m2 26.12 (23.85–28.73)
moking status at study entry
1–10 cigarettes daily 118 (12%)
11–20 cigarettes daily 88 (9%)
20 cigarettes daily 95 (9%)
rterial hypertension 711 (70%)
yperlipidemia 686 (67%)
otal cholesterol, mg/dl 204 (176–238)
DL cholesterol, mg/dl 118 (93–147)
DL cholesterol, mg/dl 49 (41–61)
istory of diabetes mellitus 238 (23%)
lycated hemoglobin A1, % 6.0 (5.6–6.5)
amily history of atherosclerosis 580 (57%)
oronary artery disease (CCS stage)
I 333 (33%)
II 207 (20%)
III 35 (3%)
istory of myocardial infarction 265 (26%)
istory of stroke 166 (16%)
aseline degree of carotid atherosclerosis,
right/left
0%–29% 663 (65%)/648 (64%)
30%–49% 90 (9%)/113 (11%)
50%–69% 165 (16%)/157 (15%)
70%–89% 50 (5%)/47 (5%)
90%–99% 11 (1%)/16 (2%)
Occlusion 40 (4%)/38 (4%)
erum creatinine, mg/dl 1.06 (0.93–1.22)
PO baseline levels, ng/ml 310 (220–416)
igh-sensitivity C-reactive protein, mg/l 3.1 (1.4–6.6)
tatin treatment at inclusion 613 (60%)
tatin treatment at follow-up 627 (62%)
CS  Canadian Cardiovascular Society classification of angina pectoris; HDL 
igh-density lipoprotein; IQR interquartile range; LDL low-density lipoprotein;
PO  myeloperoxidase.ccording to the baseline degree of stenosis, 20 (4.0%) of
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June 6, 2006:2212–8 Myeloperoxidase and HDL98 patients with carotid plaques, 11 (11.1%) of 99 with
dvanced plaques, 36 (16.0%) of 225 patients with moderate
tenosis, and 33 (17.6%) of 188 patients with high-grade
tenosis showed a progression (p  0.001). In the entire
roup of 1,019 patients the change in PSVICA as a contin-
ous surrogate marker for the degree of carotid stenosis
rom baseline to follow-up was median 0.01 m/s (IQR
0.01 to 0.11 m/s); in the 100 of 1,019 patients with a
rogressive lesion the increase in PSVICA was median 0.54
/s (IQR 0.34 to 1.03 m/s). Eight patients (0.8%) devel-
ped a de novo occlusion of a carotid artery; all of these
atients had an ipsilateral subocclusive stenosis (90% to
9%) at baseline. None of the patients underwent a carotid
evascularization procedure during the follow-up period, 10
atients (1%) had ipsilateral neurologic events, and none of
he patients showed regression of the disease by one or more
ategory.
PO, lipoproteins, and disease progression. The MPO
evel at baseline was associated with progressive disease
uring follow-up: patients with a progressive stenosis by at
east one category had significantly higher baseline MPO
evels (median 369 ng/ml, IQR 264 to 445 ng/ml) com-
ared with patients with stable disease (median MPO 304
g/ml, IQR 216 to 409 ng/ml; p  0.014). The HDL-C
p  0.95) and LDL-C (p  0.30) baseline levels were not
ignificantly associated with disease progression. Consistent
ndings were observed when considering the change of
SVICA from baseline to follow-up as a continuous measure
f progressive carotid disease: MPO (r 0.083; p 0.008),
ut not HDL-C (r  0.27; p  0.39) or LDL-C (r 
.001; p  0.98), was significantly correlated to the change
n PSVICA.
Analyzing MPO and HDL-C jointly, it seemed that
articularly patients with MPO 310 ng/ml and simulta-
eously HDL 49 mg/dl frequently showed progression of
he degree of stenosis (Fig. 1). Formal statistical testing
sing multiplicative interaction terms and log likelihood
atio tests confirmed a significant interaction between
hese parameters: MPO 310 ng/ml was significantly
ssociated with progressive disease (adjusted OR 2.57,
5% CI 1.39 to 4.75; p  0.003) only in patients with
DL-C levels 49 mg/dl (Table 3). Otherwise, in
atients with higher HDL-C levels (49 mg/dl), MPO
310 ng/ml was not significantly associated with an
ncreased risk (adjusted OR 1.42, 95% CI 0.72 to 2.78;
 0.31). Figure 2 displays adjusted ORs for progression
f disease according to baseline MPO (ptrend  0.029)
nd HDL-C (ptrend  0.47) levels separately and when
ombining these parameters.
Analyzing MPO and LDL-C jointly revealed no signif-
cant interaction between high and low MPO (by the median
f 310 ng/ml), high and low LDL cholesterol levels (by the
edian of 118 mg/dl), and progression of the disease. Com-ared with patients with low MPO and simultaneously low 1DL-C (reference group), the adjusted hazard ratio for pro-
ressive disease of patients with MPO 310 ng/ml and
DL-C 118 mg/dl was 1.72 (95% CI 1.01 to 3.08), of
atients with MPO 310 ng/ml and LDL-C 118 mg/dl it
as 1.77 (95% CI 1.01 to 3.08), and of patients with MPO
310 ng/ml and LDL-C 118 mg/dl it was 0.81 (95% CI
.41 to 1.61), indicating that MPO 310 ng/ml was associ-
ted with disease progression irrespective of the LDL-C level.
PO and inflammation. The MPO was weakly corre-
ated to hs-CRP (r  0.18; p  0.001), SAA (r  0.10;
 0.002), fibrinogen (r 0.12, p 0.001), and leukocyte
ounts (r  0.21; p  0.001). Additionally adjusting the
ultivariable model for the individual’s levels of hs-CRP (or
lternatively SAA/fibrinogen/leucocytes) slightly attenuated
he association between MPO and progression of disease:
djusted ORs for disease progression for increasing quartiles
f MPO were 1.08 (95% CI 0.55 to 2.14), 1.58 (95% CI
.84 to 2.99), and 2.06 (95% CI 1.18 to 3.81) and for
ncreasing quartiles of hs-CRP were 1.54 (95% CI 0.66 to
.59), 1.88 (95% CI 0.82 to 4.31), and 2.60 (95% CI 1.18
o 6.72) compared with the respective lowest quartiles,
uggesting that MPO predicts progressive disease indepen-
ently of hs-CRP.
Similarly, adjusting the interaction model of MPO and
DL-C for hs-CRP levels (quartiles) revealed only a
odest effect modification. Elevated MPO still was signif-
cantly associated with progressive disease (adjusted OR
.14, 95% CI 1.15 to 4.08; p  0.017) only in patients with
DL-C levels 49 mg/dl; otherwise, in patients with
DL levels 49 mg/dl, MPO 310 ng/ml was not
ignificantly associated with an increased risk (adjusted OR
igure 1. Frequency of patients with progression of carotid artery disease,
easured by duplex ultrasound, according to myeloperoxidase (MPO, in
uartiles) and high-density lipoprotein (HDL, in quartiles) levels..05, 95% CI 0.57 to 1.92; p  0.88).
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Myeloperoxidase and HDL June 6, 2006:2212–8ISCUSSION
e found that MPO is significantly associated with pro-
ression of atherosclerotic disease, particularly in patients
ith HDL-C levels 49 mg/dl, whereas in patients with
DL-C 49 mg/dl MPO did not predict disease progres-
ion. This effect was independent from other markers of
nflammation.
There is substantial evidence that oxidative processes are
ey features in the pathogenesis of atherosclerosis. Several
tudies demonstrated a potential link between the hemo-
rotein MPO and the development of coronary artery
isease, mainly through its role in lipid peroxidation, nitric
xide consumption, and inflammatory mechanisms leading
o endothelial dysfunction and plaque destabilization
8,11,21). Consistently, subjects with MPO deficiency seem
ardioprotected (26), and individuals with polymorphisms
or MPO linked to decreased expression similarly appear to
ave fewer cardiac events or evidence of cardiac disease
27–29). Furthermore, expression of human MPO by mac-
ophages was recently reported to promote atherosclerosis in
ice (22). Systemic levels of MPO are correlated to
therosclerotic burden and the incidence of cardiac events in
atients with chest pain, and they predict outcome of
atients with acute coronary syndromes (3,4). However,
hese observations relied on clinical surrogate markers of
rogressive atherosclerotic disease. Our present observation
irectly demonstrates an association between MPO and
Table 3. Multivariable Logistic Regression An
Atherosclerotic Lesions Measured by Duplex U
Patients From Baseline to Follow-Up (Median
MPO 310 ng/ml and HDL-C 49 mg/dl (n  2
MPO 310 ng/ml and HDL-C 49 mg/dl (n  2
MPO 310 ng/ml and HDL-C 49 mg/dl (n  2
MPO 310 ng/ml and HDL-C 49 mg/dl (n  2
Age
Female gender
Body mass index
Current smoker at study entry
Arterial hypertension
Low-density lipoprotein cholesterol, mg/dl
Glycated hemoglobin A1, %
Family history of atherosclerosis
History of myocardial infarction
History of stroke
Serum creatinine
Absence of statin therapy
Baseline degree of stenosis
0%–29%
30%–49%
50%–69%
70% and above
*To account for the interaction between myeloperoxidase
grouped patients using the respective medians of MPO and
310 ng/ml and HDL-C49 mg/dl; 2) MPO310 ng/ml
mg/dl; and 4) MPO 310 ng/ml and HDL-C 49 mg/dl
CI  confidence interval; OR  odds ratio; other abbrevrogression of the disease. This effect was independent of phe level of systemic inflammation as measured by acute
hase parameters and might indicate the underlying activa-
ion of leukocytes as a major contributor to progressive ath-
rosclerotic disease (12,30,31). However, further studies are
eeded to determine whether this reflects a causal relationship
nd whether MPO specifically exerts proatherogenic effects.
An inverse correlation between HDL-C levels and the
ncidence of cardiovascular events has been demonstrated in
umerous epidemiologic studies (32,33). The beneficial
ardioprotective properties of HDL are attributed to its role
n reverse cholesterol transport and its antioxidant and
nti-inflammatory functions (34,35). Recent data suggest a
eleterious effect of MPO on HDL, leading to dysfunc-
ional HDL and impaired reverse cholesterol transport
14–16). Myeloperoxidase directly binds to apolipoprotein
1, the major protein component of HDL, thereby facili-
ating its oxidative modification (15). The results of the
resent study corroborate these in vitro findings and extend
hem to the clinical setting of carotid atherosclerosis: Pa-
ients with high baseline MPO levels showed an increased
isk for progression of carotid stenosis only when they
imultaneously had low HDL-C levels. Low HDL-C, in
tates of high MPO may serve to exaggerate the proathero-
enic effects of MPO and thus uncover a severe atheroscle-
otic phenotype, suggesting that this interaction is of direct
iologic impact and seems to be titrated by the amount of
DL-C available. No such interaction was observed for
DL-C, because high MPO was associated with disease
Assessing the Risk for Progression of
ound in the Carotid Arteries of 1,019
Months, Range 6 to 9 Months)*
OR 95% CI p Value
1.0 — —
0.96 0.48–1.93 0.90
1.42 0.82–2.78 0.31
2.57 1.39–4.75 0.003
1.02 0.99–1.04 0.18
0.91 0.56–1.46 0.68
1.00 0.95–1.06 0.98
1.26 0.78–2.03 0.35
0.95 0.57–1.59 0.84
0.99 0.99–1.01 0.42
1.01 0.99–1.01 0.41
0.85 0.54–1.33 0.48
0.91 0.55–1.49 0.71
1.16 0.69–1.97 0.58
1.62 0.66–2.18 0.23
1.14 0.70–1.84 0.60
0.001
1.0 —
0.94 0.20–4.42
2.90 0.60–13.95
4.51 1.01–20.29
) and high-density lipoprotein-cholesterol (HDL-C), we
C levels as cut-off values, resulting in four groups: 1) MPO
DL-C49 mg/dl; 3) MPO310 ng/ml and HDL-C49
nce group).
s as in Table 2.alysis
ltras
7.5
63)
45)
38)
73)
(MPO
HDL-
and Hrogression irrespective of patients’ LDL-C levels.
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June 6, 2006:2212–8 Myeloperoxidase and HDLConsistent with a recent report (3), MPO serum levels of
atients enrolled in the ICARAS protocol, all with high
therosclerotic burden, were higher than those described for
ealthy subjects (36) using comparable analytical methods.
ecause blood was obtained from a peripheral vein, and taking
nto account the widespread activation of leukocytes described
n atherosclerotic vessels (12), the local MPO levels in the
therosclerotic carotid arteries might even be higher than the
evels measured systemically. Measurement of MPO serum
evels seems to add to the risk stratification of patients with
dvanced carotid atherosclerosis and supports the rationale that
harmacologic inhibition of MPO might be a potential future
ntiatherosclerotic strategy. Interestingly, MPO independently
rom hs-CRP predicted atherosclerosis progression and thus
dds to the prognostic value of this global marker of inflam-
ation. However, no significant interaction between MPO,
s-CRP, and HDL-C was found, suggesting that a multi-
iomarker approach including MPO and hs-CRP jointly
id not increase the diagnostic utility.
tudy limitations. As described for the ICARAS proto-
igure 2. Forrest plot describing the risk for progression of carotid atherosc
interquartile range 6 to 9 months) calculated by multivariable logistic regre
f atherosclerotic disease, hypertension, current smoking, glycated hemo
yocardial infarction, history of stroke, stain therapy, and baseline degre
ipoprotein; MPO  myeloperoxidase.ol, some limitations of the present study have to be lcknowledged. The potential selection bias inherent in a
onsecutive series of duplex examinations cannot be ruled
ut, and the generalizability of the findings to younger
ndividuals with lower atherosclerotic burden or to un-
elected population-based samples remains to be deter-
ined. Direct demonstration of the action of MPO on
DL-C in carotid atherosclerotic plaques was beyond
he scope of this epidemiologic project, and the proof of
causal relationship between MPO, HDL-C, and pro-
ression of atherosclerosis remains to be provided by
xperimental in vitro and in vivo data.
Intima-media thickness (IMT) measurements were not
erformed in these patients, although it is a sensitive
arameter for progression of early stages of atherosclerosis.
ur results have to be interpreted in the context of progres-
ive atherosclerotic stenosis, and different findings may be
bserved when analyzing IMT progression.
onclusions. Myeloperoxidase was associated with pro-
ression of carotid atherosclerosis in patients with HDL-C
s by duplex ultrasound from baseline to follow-up after median 7.5 months
analysis. Models adjusted for age, gender, body mass index, family history
n A1, low-density lipoprotein cholesterol, serum creatinine, history of
carotid atherosclerosis. CI  confidence interval; HDL  high-densitylerosi
ssion
globievels 49 mg/dl.
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